UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

The New England journal of medicine, 2014-11, Vol.371 (20), p.1867-1876

2014

Volltextzugriff (PDF)

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

The lancet oncology, 2017-05, Vol.18 (5), p.611-622

2017

Volltextzugriff (PDF)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF -mutant metastatic melanoma: a phase 2 double-blind randomised study

The lancet oncology, 2013-07, Vol.14 (8), p.733-740

2013

Volltextzugriff (PDF)

Prognostic impact of B-cell density in cutaneous melanoma

Cancer Immunology, Immunotherapy, 2011-12, Vol.60 (12), p.1729-1738

2011

Volltextzugriff (PDF)

HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab

Pathology oncology research, 2022-04, Vol.28, p.1610297-1610297

2022

Volltextzugriff (PDF)

Therapeutic and Adverse Effect of Anti-PD1 Immunotherapy in Melanoma: A Retrospective, Single-Institute Study of 222 Patients

Cancers, 2023-08, Vol.15 (15), p.3966

2023

Volltextzugriff (PDF)

Predictive and Prognostic Value of BRAF and NRAS Mutation of 159 Sentinel Lymph Node Cases in Melanoma—A Retrospective Single-Institute Study

Cancers, 2021-06, Vol.13 (13), p.3302

2021

Volltextzugriff (PDF)

Changing Trends in Melanoma Incidence and Decreasing Melanoma Mortality in Hungary Between 2011 and 2019: A Nationwide Epidemiological Study

Frontiers in oncology, 2021-02, Vol.10, p.612459-612459

2021

Volltextzugriff (PDF)

Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Pathology oncology research, 2020-01, Vol.26 (1), p.317-325

2020

Volltextzugriff (PDF)

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

Journal for immunotherapy of cancer, 2020-06, Vol.8 (1), p.e000391

2020

Volltextzugriff (PDF)

Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report

Journal of medical case reports, 2022-10, Vol.16 (1), p.1-396, Article 396

2022

Volltextzugriff (PDF)

The Role of Stereotactic Radiotherapy in the Management of Melanoma, A Retrospective Single Institute Preliminary Study of 30 Patients

Pathology oncology research, 2022-09, Vol.28, p.1610550

2022

Volltextzugriff (PDF)

Improving Quality Indicator of Melanoma Management - Change of Melanoma Mortality-to-Incidence Rate Ratio Based on a Hungarian Nationwide Retrospective Study

Frontiers in oncology, 2021-10, Vol.11, p.745550-745550

2021

Volltextzugriff (PDF)

Tumor-Associated Disialylated Glycosphingolipid Antigen-Revealing Antibodies Found in Melanoma Patients' Immunoglobulin Repertoire Suggest a Two-Direction Regulation Mechanism Between Immune B Cells and the Tumor

Frontiers in immunology, 2019-04, Vol.10, p.650-650

2019

Volltextzugriff (PDF)

Urogenitalis lokalizációjú mucosamelanoma primer és áttétes esetei klinikánkon

Orvosi hetilap, 2019-03, Vol.160 (10), p.378-385

2019

Volltextzugriff (PDF)

307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A334-A334

2020

Volltextzugriff (PDF)

Epileptic Seizure Provoked by Bone Metastasis of Chronic Lymphoid Leukemia and Merkel Cell Carcinoma

Case reports in medicine, 2020-10, Vol.2020 (2020), p.1-4

2020

Volltextzugriff (PDF)

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

The lancet oncology, 2018-05, Vol.19 (5), p.603-615

2018

Volltextzugriff (PDF)

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

The lancet oncology, 2018-10, Vol.19 (10), p.1315-1327

2018

Volltextzugriff (PDF)

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma

Journal of clinical oncology, 2022-12, Vol.40 (36), p.4178-4188

2022

Volltextzugriff (PDF)

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma

European journal of cancer (1990), 2020-02, Vol.126, p.33-44

2020

Volltextzugriff (PDF)

Clinical studies and accepted therapies of advanced melanoma

Magyar onkologia, 2016-03, Vol.60 (1), p.11

Liszkay, Gabriella

2016

Volltextzugriff (PDF)

Advancements in the diagnosis of melanoma

Magyar onkologia, 2015-03, Vol.59 (1), p.68

Liszkay, Gabriella

2015

Volltextzugriff (PDF)

Elektrokemoterápia áttétes melanomában

Orvosi hetilap, 2023-09, Vol.164 (35), p.1381-1386

2023

Volltextzugriff (PDF)

1 – 25 von 102

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(73)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF -mutant metastatic melanoma: a phase 2 double-blind randomised study

Prognostic impact of B-cell density in cutaneous melanoma

HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab

Therapeutic and Adverse Effect of Anti-PD1 Immunotherapy in Melanoma: A Retrospective, Single-Institute Study of 222 Patients

Predictive and Prognostic Value of BRAF and NRAS Mutation of 159 Sentinel Lymph Node Cases in Melanoma—A Retrospective Single-Institute Study

Changing Trends in Melanoma Incidence and Decreasing Melanoma Mortality in Hungary Between 2011 and 2019: A Nationwide Epidemiological Study

Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report

The Role of Stereotactic Radiotherapy in the Management of Melanoma, A Retrospective Single Institute Preliminary Study of 30 Patients

Improving Quality Indicator of Melanoma Management - Change of Melanoma Mortality-to-Incidence Rate Ratio Based on a Hungarian Nationwide Retrospective Study

Tumor-Associated Disialylated Glycosphingolipid Antigen-Revealing Antibodies Found in Melanoma Patients' Immunoglobulin Repertoire Suggest a Two-Direction Regulation Mechanism Between Immune B Cells and the Tumor

Urogenitalis lokalizációjú mucosamelanoma primer és áttétes esetei klinikánkon

307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study

Epileptic Seizure Provoked by Bone Metastasis of Chronic Lymphoid Leukemia and Merkel Cell Carcinoma

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma

Clinical studies and accepted therapies of advanced melanoma

Advancements in the diagnosis of melanoma

Elektrokemoterápia áttétes melanomában

Suchergebnisse filtern